Japan Depression Therapeutics Market Report 2022 to 2030

Japan Depression Therapeutics Market Analysis

$ 3999

The Japan depression therapeutics market is expected to witness growth from $628 Mn in 2022 to $978 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-2030. The growth in research and development initiatives in Japan and the increasing prevalence of depression among the Japanese population are driving the growth of the market. The Japan depression therapeutics market is segmented by drug type, therapies, indication, and by end users. Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, and AstraZeneca are the major players in the Japan depression therapeutics market.

ID: IN10JPPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Dr. Parul Choudhary

Buy Now

Japan Depression Therapeutics Market Executive Analysis

The Japan depression therapeutics market size is at around $628 Mn in 2022 and is projected to reach $978 Mn in 2030, exhibiting a CAGR of 5.7% during the forecast period. With various trends in age groups, the total yearly medical spending in Japan in FY 2050 would be $535.1-584.0 Bn, which is 1.3-1.5 times higher than that in FY 2018. If the effect of the spread of drug usage was considered, it was predicted that the cumulative total medical care spending would decline by approximately $7.2-9.0 Bn. On the other hand, the cumulative total medical care spending was projected to increase by approximately $68.7-106.5 Bn as a result of the ongoing rise in cancer-related medical costs.

Teenage depression is an increasing issue in Japan. According to the Japanese Ministry of Health, Labor, and Welfare, depression affects one in ten adolescents between the ages of 12 and 18. Additionally, since 2006, the incidence of teenage suicide has been steadily rising. 617 teenagers committed suicide in 2018, a 9% rise from 2017.

In Japan, fluvoxamine was the first SSRI (selective serotonin reuptake inhibitor) to be made available for therapeutic use. The first serotonin noradrenaline reuptake inhibitor (SNRI), milnacipran, and another SSRI, paroxetine, have since been introduced in Japan. As a result, as in many other nations, all forms of new-generation antidepressants are now clinically accessible in Japan. These modifications have elevated depression drug treatment in Japan to a new level. Selective monoamine reuptake inhibitors produce much fewer side effects than tricyclic or tetracyclic antidepressants, but they have an equal antidepressant effect. Additionally, these medications are generally safe even for elderly and/or weakened patients due to negative impacts on the cardiovascular and nervous systems. Contrary to tricyclic antidepressants, these medications are rarely fatal even when consumed in excess during a suicide attempt.

Japan Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

In Japan, depression affects an estimated 6 Mn people and is a prevalent mental health disorder. The demand for depression therapeutics in the nation is being driven by the increasing prevalence of depression. A lot of research and development is being done in the area of depression therapeutics, and this is resulting in the creation of brand-new, modern medicines. Patients' demand for new, more efficient treatments is causing the Japanese depression therapeutics market to expand.

Market Restraints

Despite increased information on mental health issues, a mental disease is still defamed in Japan. This may dissuade patients from looking for therapy for their depression, which may confine the market's expansion for depression therapeutics. The severe regulatory setting for depression therapeutics in Japan can make it challenging for businesses to launch innovative medications. This may restrict access to new therapies and restrain the Japan depression therapeutics market growth. Japan offers a diversity of complementary and alternative medical practices, as well as conventional Japanese medicine, as treatments for depression. The market for depression therapeutics may not develop as rapidly as it might otherwise due to the perception that these treatments are more natural and less invasive than pharmaceuticals.

Competitive Landscape

Key Players

Santen Pharmaceutical (JPN)
Sumitomo Dainippon Pharma (JPN)
Daiichi Sankyo (JPN)
Kyowa Hakko Kirin (JPN)
Mitsubishi Tanabe Pharma (JPN)
AstraZeneca
GlaxoSmithKline
Elly Lilly
Allergan
Takeda Pharmaceutical
Intellipharmaceutics
Otsuka Holdings

Healthcare Policies and Regulatory Landscape

Japan's population is largely covered by a universal health insurance program. National health insurance (NHI) and employee health insurance (EHI) are the two primary kinds of health insurance in Japan, both of which are required by the government for all residents. Outpatient and inpatient treatment for depression under NHI is covered, as are counselling and medication. The sort of drug and the dosage can affect the reimbursement rates for depression medications, though. For their therapy, patients might have to make a co-pay or co-insurance payment. Employers offer EHI, which includes a variety of medical services, including outpatient and inpatient treatment for depression. Determining the policy’s coverage and reimbursement amounts for depression medication.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

Antidepressants
Anxiolytics
Anticonvulsants
Noradrenergic Agents
Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

Electroconvulsive Therapy (ECT)
Cognitive Behaviour Therapy (CBT)
Psychotherapy
Deep Brain Stimulation
Transcranial Magnetic Stimulation (TMS)
Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

Major Depressive Disorder (MDD)
Bipolar Disorder
Dysthymic Disorder
Postpartum Depression
Seasonal Affective Disorder (SAD)
Premenstrual Dysphoric Disorder (PMDD)
Others

By End Users (Revenue, USD Billion):

NGOs
Asylums
Hospitals
Mental Healthcare Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.